Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.

Jorge S, Swisher EM, Norquist BM, Pennington KP, Gray HJ, Urban RR, Garcia RL, Doll KM.

Gynecol Oncol Rep. 2019 Aug 9;29:113-117. doi: 10.1016/j.gore.2019.08.001. eCollection 2019 Aug.

2.

An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.

Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]

PMID:
31033800
3.

Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.

Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, Swisher EM.

Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.

PMID:
30803719
4.

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.

Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.

PMID:
30661763
5.

Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.

Pennington KP, Urban RR, Gray HJ.

J Natl Compr Canc Netw. 2019 Jan;17(1):86-90. doi: 10.6004/jnccn.2018.7263. Review.

PMID:
30659132
6.

Evaluation of Intraoperative Assessments in the Management of Endometrial Carcinoma: A Retrospective Quality Assurance Review.

Strickland SV, Rendi MH, Garcia RL, Norquist BS, Pennington KP, Kilgore MR.

Int J Gynecol Pathol. 2018 Sep;37(5):414-420. doi: 10.1097/PGP.0000000000000445.

PMID:
30102260
7.

The role of physical activity in breast and gynecologic cancer survivorship.

Pennington KP, McTiernan A.

Gynecol Oncol. 2018 Apr;149(1):198-204. doi: 10.1016/j.ygyno.2018.01.020. Epub 2018 Feb 1. Review.

PMID:
29395306
8.

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.

Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, Swisher EM.

Gynecol Oncol. 2018 Feb;148(2):281-285. doi: 10.1016/j.ygyno.2017.12.004. Epub 2017 Dec 9.

PMID:
29233532
9.

DNA repair mutations and outcomes in ovarian cancer--response.

Swisher EM, Norquist BM, Pennington KP, Rendi MH, Garcia RL.

Clin Cancer Res. 2015 Feb 1;21(3):659. doi: 10.1158/1078-0432.CCR-14-2805. No abstract available.

10.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.

Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

11.

Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.

Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM.

Gynecol Oncol. 2013 Mar;128(3):483-7. doi: 10.1016/j.ygyno.2012.12.015. Epub 2012 Dec 19.

12.

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.

Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.

13.

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, Swisher EM.

Cancer. 2013 Jan 15;119(2):332-8. doi: 10.1002/cncr.27720. Epub 2012 Jul 18.

14.

Hereditary ovarian cancer: beyond the usual suspects.

Pennington KP, Swisher EM.

Gynecol Oncol. 2012 Feb;124(2):347-53. doi: 10.1016/j.ygyno.2011.12.415. Review.

PMID:
22264603
15.

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM.

Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7. doi: 10.1073/pnas.1115052108. Epub 2011 Oct 17.

16.

Insulin resistance influences central opioid activity in polycystic ovary syndrome.

Berent-Spillson A, Love T, Pop-Busui R, Sowers M, Persad CC, Pennington KP, Eyvazaddeh AD, Padmanabhan V, Zubieta JK, Smith YR.

Fertil Steril. 2011 Jun 30;95(8):2494-8. doi: 10.1016/j.fertnstert.2011.03.031. Epub 2011 Apr 12.

17.

The role of the endogenous opioid system in polycystic ovary syndrome.

Eyvazzadeh AD, Pennington KP, Pop-Busui R, Sowers M, Zubieta JK, Smith YR.

Fertil Steril. 2009 Jul;92(1):1-12. doi: 10.1016/j.fertnstert.2009.05.012. Review.

PMID:
19560572

Supplemental Content

Loading ...
Support Center